Linked Life Data

19178667

Source:http://linkedlifedata.com/resource/pubmed/id/19178667

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19178667rdf:typepubmed:Citationlld:pubmed
pubmed-article:19178667lifeskim:mentionsumls-concept:C0024299lld:lifeskim
pubmed-article:19178667lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:19178667lifeskim:mentionsumls-concept:C0012984lld:lifeskim
pubmed-article:19178667lifeskim:mentionsumls-concept:C0010711lld:lifeskim
pubmed-article:19178667lifeskim:mentionsumls-concept:C1517677lld:lifeskim
pubmed-article:19178667lifeskim:mentionsumls-concept:C0332287lld:lifeskim
pubmed-article:19178667lifeskim:mentionsumls-concept:C0442711lld:lifeskim
pubmed-article:19178667lifeskim:mentionsumls-concept:C1705241lld:lifeskim
pubmed-article:19178667lifeskim:mentionsumls-concept:C1705242lld:lifeskim
pubmed-article:19178667pubmed:issue2lld:pubmed
pubmed-article:19178667pubmed:dateCreated2009-1-30lld:pubmed
pubmed-article:19178667pubmed:abstractTextCytosine arabinoside (ara-C) is a component of many protocols for the treatment of acute leukaemia and non-Hodgkin lymphomas in humans. The aim of the study was to prospectively evaluate the efficacy of ara-C in a myeloablative regimen in a cohort of canine lymphomas with bone marrow involvement. Seventeen dogs were enrolled. Eight were treated with a VCAA-based protocol (Group 1) and nine with the same regimen added with ara-C (Group 2). Ara-C was administered on a 5-day schedule as an i.v. continuous infusion at the dose of 150 mg m(-2) per day for five consecutive days. During treatment complete remission (CR) was achieved in two dogs in Group 1 and in eight dogs in Group 2. CR rate was significantly higher in Group 2 (P < 0.01). Median survival was 72.5 days (range 6-174) in Group 1 and 243 days (range 73-635) in Group 2. Survival was significantly longer in Group 2 (P < 0.001). Both protocols were well tolerated, with a low incidence of adverse events. Ara-C added to a VCAA-based protocol appears to be safe and beneficial in dogs with stage V lymphoma. Incorporation of the nucleoside analogue might be crucial for the development of future therapeutic strategies in dogs.lld:pubmed
pubmed-article:19178667pubmed:languageenglld:pubmed
pubmed-article:19178667pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19178667pubmed:citationSubsetIMlld:pubmed
pubmed-article:19178667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19178667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19178667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19178667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19178667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19178667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19178667pubmed:statusMEDLINElld:pubmed
pubmed-article:19178667pubmed:monthJunlld:pubmed
pubmed-article:19178667pubmed:issn1476-5829lld:pubmed
pubmed-article:19178667pubmed:authorpubmed-author:RomanelliGGlld:pubmed
pubmed-article:19178667pubmed:authorpubmed-author:ZinkCClld:pubmed
pubmed-article:19178667pubmed:authorpubmed-author:ComazziSSlld:pubmed
pubmed-article:19178667pubmed:authorpubmed-author:LorenzeM DMDlld:pubmed
pubmed-article:19178667pubmed:authorpubmed-author:MarconatoLLlld:pubmed
pubmed-article:19178667pubmed:authorpubmed-author:BonfantiUUlld:pubmed
pubmed-article:19178667pubmed:authorpubmed-author:StefanelloDDlld:pubmed
pubmed-article:19178667pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19178667pubmed:volume6lld:pubmed
pubmed-article:19178667pubmed:ownerNLMlld:pubmed
pubmed-article:19178667pubmed:authorsCompleteYlld:pubmed
pubmed-article:19178667pubmed:pagination80-9lld:pubmed
pubmed-article:19178667pubmed:meshHeadingpubmed-meshheading:19178667...lld:pubmed
pubmed-article:19178667pubmed:meshHeadingpubmed-meshheading:19178667...lld:pubmed
pubmed-article:19178667pubmed:meshHeadingpubmed-meshheading:19178667...lld:pubmed
pubmed-article:19178667pubmed:meshHeadingpubmed-meshheading:19178667...lld:pubmed
pubmed-article:19178667pubmed:meshHeadingpubmed-meshheading:19178667...lld:pubmed
pubmed-article:19178667pubmed:meshHeadingpubmed-meshheading:19178667...lld:pubmed
pubmed-article:19178667pubmed:meshHeadingpubmed-meshheading:19178667...lld:pubmed
pubmed-article:19178667pubmed:meshHeadingpubmed-meshheading:19178667...lld:pubmed
pubmed-article:19178667pubmed:meshHeadingpubmed-meshheading:19178667...lld:pubmed
pubmed-article:19178667pubmed:meshHeadingpubmed-meshheading:19178667...lld:pubmed
pubmed-article:19178667pubmed:meshHeadingpubmed-meshheading:19178667...lld:pubmed
pubmed-article:19178667pubmed:meshHeadingpubmed-meshheading:19178667...lld:pubmed
pubmed-article:19178667pubmed:meshHeadingpubmed-meshheading:19178667...lld:pubmed
pubmed-article:19178667pubmed:meshHeadingpubmed-meshheading:19178667...lld:pubmed
pubmed-article:19178667pubmed:meshHeadingpubmed-meshheading:19178667...lld:pubmed
pubmed-article:19178667pubmed:meshHeadingpubmed-meshheading:19178667...lld:pubmed
pubmed-article:19178667pubmed:meshHeadingpubmed-meshheading:19178667...lld:pubmed
pubmed-article:19178667pubmed:meshHeadingpubmed-meshheading:19178667...lld:pubmed
pubmed-article:19178667pubmed:year2008lld:pubmed
pubmed-article:19178667pubmed:articleTitleCytosine arabinoside in addition to VCAA-based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference?lld:pubmed
pubmed-article:19178667pubmed:affiliationClinica Veterinaria L'Arca, Naples, Italy. lauramarconato@yahoo.itlld:pubmed
pubmed-article:19178667pubmed:publicationTypeJournal Articlelld:pubmed